{"id":"NCT02469857","sponsor":"Atox Bio Ltd","briefTitle":"Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections","officialTitle":"Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-01","primaryCompletion":"2019-08-18","completion":"2019-10-18","firstPosted":"2015-06-12","resultsPosted":"2021-10-05","lastUpdate":"2021-10-05"},"enrollment":290,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Necrotizing Soft Tissue Infections","Necrotizing Fasciitis","Fournier's Gangrene"],"interventions":[{"type":"DRUG","name":"AB103 0.5 mg/kg","otherNames":["reltecimod"]},{"type":"OTHER","name":"NaCl 0.9%","otherNames":["Normal saline"]}],"arms":[{"label":"AB103 0.5 mg/kg","type":"EXPERIMENTAL"},{"label":"NaCl 0.9%","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections (NSTI) receiving standard of care therapy.","primaryOutcome":{"measure":"Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE)","timeFrame":"28 days","effectByArm":[{"arm":"Reltecimod (AB103) 0.5 mg/kg","deltaMin":69,"sd":null},{"arm":"Placebo","deltaMin":59,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.135"},{"comp":"OG000 vs OG001","p":"0.025"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":71,"countries":["United States","France"]},"refs":{"pmids":["32657946"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":143},"commonTop":["Pneumonia","Atrial fibrillation","Anemia","Diarrhea"]}}